Gloria Pharmaceuticals announced to plan to privately issue stocks to raise fund of not exceeding 6 billion yuan on January 24, wherein, 2.389 billion yuan would be used to purchase 85.01% equity of Shanxi Powerdone, which will be the fifth M&A transaction of Gloria in recent five years and another M&A "drama" led by Chinese pharmaceutical enterprises in the pharmaceutical market following Luye Pharma's 6.3 billion to wholly own and control Jialin Pharmaceutical.
According to the plan to privately issue stocks of A Shares announced by Gloria Pharmaceuticals on January 24, the company planned to issue less than 0.274 billion stocks at a price of 21.93 yuan/stock to ten specific investors, and planned to raise fund of not exceeding 6.0 billion yuan. In details, the company planned to purchase 85.01% equity of Shanxi Powerdone with 2.389 billion yuan; invest 0.407 billion yuan to the "Production expansion project of Ginkgolide B injection workshop of Guangzhou Xinhuacheng Biotech Co., Ltd."; invest 0.361 billion yuan to the "Integrated workshop project of Aonuo (China) Pharmaceuticals"; invest 0.209 billion yuan to the "Construction project of network management system of sales terminal of the Marketing Center of the company"; invest 0.17 billion yuan to the "Information construction project of the company"; and use the rest 2.464 billion yuan for supplementing the circulating fund of the company.
Furthermore, 8 in the 10 subscription objects are associated with listed companies, with a subscription amount of up to 5.109 billion yuan.
